# Ipamorelin: Research Overview — Peptide Cycles > A data-forward literature summary of ipamorelin, a selective ghrelin-receptor (GHS-R1a) agonist studied for GH release. Covers mechanism, the Phase 2 postoperative-ileus trial, pharmacokinetics, reported effects, and cited safety cautions. The most receptor-selective growth hormone secretagogue in this class — and, on its one completed human efficacy trial, a compound whose primary endpoint was not met. ## The short version Ipamorelin is the lead compound on this desk — a small, five-amino-acid peptide built to activate the ghrelin receptor (also called GHS-R1a), the same receptor the "hunger hormone" ghrelin normally uses. Activating this receptor triggers a pulse of growth hormone (GH) release from the pituitary gland. What sets ipamorelin apart from older compounds in its class is selectivity: at doses far higher than what it takes to release GH, it does not meaningfully raise cortisol or prolactin, two stress- and reproduction-related hormones that older GH-releasing peptides tend to push up alongside GH. Ipamorelin's human evidence, though, is thin and mixed. A pharmacokinetic study in eight healthy men established how quickly it clears the body and how a single dose produces one clean pulse of GH [9]. But its only completed efficacy trial — a Phase 2 study in patients recovering from bowel surgery — did not reach statistical significance on its main measure [8]. Ipamorelin has never been approved as a medicine anywhere, and nothing here is a recommendation for how it should be used. ## What it is Ipamorelin is a synthetic pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 — alpha-aminoisobutyric acid at position 1, plus D-2-naphthylalanine and D-phenylalanine, unusual amino acids chosen specifically to resist the enzymes that would otherwise break the molecule down quickly. It was derived from an earlier compound, GHRP-1, by removing a central two-amino-acid segment, a design change that sharpened its receptor selectivity. It acts on the ghrelin receptor (GHS-R1a), the same receptor targeted by the natural appetite hormone ghrelin, but its downstream effect of interest here is GH release rather than appetite. Ipamorelin's founding characterization, published in 1998, established it as "the first selective growth hormone secretagogue": it released GH potently across rat pituitary cells, anesthetized rats, and conscious swine — where its effective dose (ED50) of 2.3 nanomol/kg was comparable to the 3.9 nanomol/kg needed for the older compound GHRP-6 — while not raising ACTH or cortisol above levels seen with GHRH alone, even at doses more than 200-fold above its GH-releasing ED50 [11]. ## How it works Ipamorelin binds the ghrelin/growth-hormone-secretagogue receptor (GHS-R1a) on pituitary somatotroph cells, triggering GH release through a signaling pathway distinct from — and complementary to — the GHRH-receptor pathway that CJC-1295 uses. Because the two compounds act on separate receptors that converge on the same GH-release outcome, they are frequently studied and used together in research contexts, on the rationale that combined receptor activation could produce a larger or more sustained GH pulse than either alone; a 2026 narrative review notes that the CJC-1295-plus-ipamorelin combination improved maximal muscle tetanic tension in a mouse model of glucocorticoid-induced muscle loss, while cautioning that the evidence for the combination remains limited to animal studies and that safety and dosing data in humans remain unknown [12]. Beyond the pituitary, GHS-R1a is also expressed on enteric and vagal neurons controlling gut motility, on pancreatic islet cells, and in hypothalamic appetite circuits — a broader expression pattern that explains why ipamorelin has been studied outside of pure GH pharmacology, including for gut-motility effects after surgery [8] and for its influence on chemotherapy-associated weight loss [6]. ## What the research shows *Founding pharmacology.* Ipamorelin's original 1998 characterization released GH potently in rat pituitary cells, anesthetized rats, and conscious swine (swine ED50 2.3 nmol/kg versus 3.9 nmol/kg for GHRP-6), without raising ACTH or cortisol above GHRH-alone levels even at doses over 200-fold its GH ED50 — the defining selectivity result for this compound [11]. *Human pharmacokinetics.* In eight healthy male volunteers per dose level, five 15-minute intravenous infusions across a 4.21-140.45 nmol/kg dose range showed dose-proportional kinetics: a terminal half-life of approximately 2 hours, clearance of 0.078 L/h/kg, and steady-state volume of distribution of 0.22 L/kg. The GH response peaked around 0.67 hours (40 minutes) post-dose as a single discrete pulse [9]. *The one completed human efficacy trial.* NCT00672074, a randomized, controlled Phase 2 study in 114 adults undergoing open or laparoscopic bowel resection, dosed ipamorelin at 0.03 mg/kg intravenously twice daily for up to 7 days. Median time to first tolerated meal was 25.3 hours with ipamorelin versus 32.6 hours with placebo — numerically faster, but not statistically significant (p=0.15). Treatment-emergent adverse events occurred in 87.5% of the ipamorelin arm versus 94.8% of the placebo arm, with no ipamorelin-specific safety signal identified in this short perioperative window [8]. *Preclinical weight-loss data.* In a 2024 ferret model of cisplatin-induced weight loss, intraperitoneal ipamorelin (1-3 mg/kg) reduced weight loss by approximately 24% on the final day of the delayed phase (48-72 hours post-cisplatin), but had no anti-emetic effect on either acute or delayed emesis — a contrast to a related compound, anamorelin, which reduced acute emesis by 60% via a central mechanism in the same study [6]. *Skeletal and combination-protocol data.* Subcutaneous ipamorelin at 18, 90, and 450 microg/day (divided three times daily) for 15 days dose-dependently increased longitudinal bone growth rate in adult female rats from 42 to 44, 50, and 52 microm/day, without measurable change in total IGF-1, IGFBPs, or bone-turnover markers — suggesting a partly local, GH-pulse-driven skeletal effect rather than a purely IGF-1-mediated one [10]. And a 2026 narrative review found that CJC-1295 combined with ipamorelin improved maximal tetanic muscle tension in a mouse model of glucocorticoid-induced muscle loss, while stating plainly that evidence remains limited to animal studies and that safety and dosing data for ipamorelin remain unknown in humans [12]. ## Reported effects, cautions & safety The controlled data above are sparse relative to how widely ipamorelin is discussed in research-use communities. What follows is anecdotal, not clinical evidence — self-reported, unverified, and never tied to a specific dose or source. *Reported benefits (anecdotal, not clinical evidence):* Deeper, more restorative sleep is the most consistently cited effect, often noticed within one to two weeks of a pre-bed routine. Vivid dreams, especially in the early weeks, are frequently described and are commonly interpreted (informally) as a sign of altered REM architecture. Faster physical recovery and reduced post-training soreness are frequently reported, and a gradual leaner body composition over weeks to months is occasionally described, generally alongside consistent training and diet. *Reported adverse effects (anecdotal, not clinical evidence):* Facial flushing and a brief head-rush shortly after injection — often compared to a niacin flush — are frequently reported, typically resolving within an hour. Tingling or numbness in the hands and feet, mild water retention and puffiness, and increased hunger in the hours after injection (consistent with ipamorelin's ghrelin-receptor mechanism) are occasionally reported. Early fatigue, dizziness, or a "spacey" feeling after injection, injection-site irritation, and a perceived diminishing response after three to four months of continuous use are also occasionally described. *Cited cautions from the clinical and preclinical literature:* - **Active or recent malignancy / proliferative conditions.** GH stimulates hepatic IGF-1, a well-characterized mitogen; chronically raising GH-pulse amplitude is a mechanism-based (not clinically observed) concern for pre-existing or occult tumors. - **Diabetes, impaired glucose tolerance, or insulin resistance.** GH reduces peripheral insulin sensitivity, and ex vivo pancreatic tissue from both normal and diabetic rats released insulin directly in response to ipamorelin via calcium-channel and adrenergic/cholinergic pathways — a dual metabolic influence with unpredictable net glycemic impact and no human glycemic data at research-use doses. - **Active cardiovascular disease, heart failure, or significant edema.** GH excess is linked to fluid retention and cardiac strain; separately, a 28-day integrated preclinical safety study of a different GHS-R1a agonist (GSK894281 — not ipamorelin) found dose-dependent myocardial degeneration and necrosis in rats, detectable by histopathology, electron microscopy, and elevated cardiac troponin [7]. No equivalent long-duration cardiovascular study of ipamorelin itself exists in any species; this is a class-level signal, not an ipamorelin-specific finding. - **Appetite dysregulation or adiposity-related conditions.** Ghrelin-receptor agonism activates hypothalamic appetite centers; ipamorelin has separately shown GH-independent stimulation of adiposity and leptin elevation in mice, indicating part of its body-composition effect operates outside the GH axis. - **Unknown long-term human safety.** The only controlled human dataset is the single Phase 2 perioperative trial (up to 7 days IV dosing) plus the acute single-dose PK study [8][9]; no Phase 3 trial exists, and subcutaneous self-administration — the dominant route in off-label use — has no published human safety or pharmacokinetic characterization. Research-grade material from unregulated suppliers is also not subject to pharmaceutical quality assurance. - **A relative safety note.** Ipamorelin's defining selectivity — minimal ACTH, cortisol, and prolactin elevation relative to older secretagogues [11] — removes one specific concern that applies to less selective compounds in its class, though it does not establish an absence of all off-target effects. ## Where it fits in the Growth Hormone Axis Ipamorelin is the lead compound on this desk because it is the most mechanistically distinct of the three: a separate receptor from [CJC-1295](/cjc-1295), a separate evidence profile from [MOTS-c](/mots-c), and — uniquely among the three — a completed human efficacy trial with a result (a missed primary endpoint) that this desk treats as data rather than downplays. Its receptor-selectivity story is the cleanest piece of pharmacology on this desk; its human trial record is the thinnest of any GH-axis-facing compound with a completed RCT. See the [comparison page](/compare) for how its protocol history stacks up next to the other two. ![Ipamorelin research illustration — abstract pulse-waveform and receptor-binding motifs in dim plum and magenta](/images/ipamorelin.webp) --- A data desk for Growth Hormone Axis peptide research — every number sourced to its study design, no doses recommended, nothing for sale.